Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells

Anti-Cancer Drugs

Volumn 15, Issue 7, 2004, Pages 671-678

  Deschatrette, J ^a   Ng, K H ^a   Gouthiere L ^b   Maigne J ^a   Guerroui, S ^a   Wolfrom, C ^a  

^a INSERM   (France)

^b Laboratory of Applied BioStatistics   (France)

Author keywords

Cell culture; Cisplatin; Hepatocarcinoma; Methotrexate; Non linear dynamics

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; METHOTREXATE; TELOMERASE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVITY; FOLLOW UP; FREQUENCY ANALYSIS; GROWTH RATE; HEPATOMA CELL; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOSOME; OBSERVATION; POPULATION; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TELOMERE; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; CLONE CELLS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; LIVER NEOPLASMS, EXPERIMENTAL; METHOTREXATE; RATS; TELOMERE;

EID: 4143124374     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000136879.96680.bc     Document Type: Article

References (33)

1. Ciaiolo C, Ferrero D, Pugliese A, Biglino A, Marletto G, Tonello M, et al. Enhancement of methotrexate cytotoxicity by modulation of proliferation activity in normal and neoplastic T lymphocytes and in a myeloid leukemia cell line. Tumori 1988; 74:537-542.
2. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 1997; 43:7-14.
3. Nakajima A, Hakoda M, Yamanaka H, Kamatani N, Kashiwazaki S. Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55:237-242.
4. Frei 3rd E, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A. The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Bone Marrow Transplant 1999; 9:939-945.
5. Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 2001; 12:23-27.
6. Kassanagh J, Tresukol D, Edwards C, Freedman R, Gonzales de Leon C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 7:1584-1588.
7. Haurie C, Dale DC, Mackey MC. Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. Blood 1998; 8:2629-2640.
8. Supino R, Rodolfo M, Mariani M, Mapelli E. Heterogeneity and phenotypic instability of chemotherapeutic and immunologic sensitivity in murine and human melanoma cell clones. Tumors 1992; 78:5-9.
9. Ferguson PJ, Cheng YC. Phenotypic instability of drug sensitivity in a human colon carcinoma cell line. Cancer Res 1989; 5:1148-1153.
10. Nissen E, Weiss H, Naundorf H, Arnold W, Tanneberger S. Investigations on the instability of drug sensitivity in dependence on culture and transplantation conditions in case of a human lung carcinoma. Arch Geschwulstforsch 1984; 6:443-450.
11. Chow M, Kong M, Rubin H. Unmasking large and persistent reductions in proliferation rate of aging cells. In vitro Cell Dev Biol 1997; 33:809-818.
12. Wolfrom C, Raynaud N, Maigné J, Papathanassiou S, Conti M, Kadhom N, et al. Periodic fluctuations in proliferative capacity of SV40 transformed human skin fibroblasts with prolonged lifespan. Cell Biol Toxicol 1994; 10:247-254.
13. Maigné J, Deschatrette J, Sarrazin S, Hecquet B, Guerroui S, Wolfrom C. The time-pattern of rises and falls in proliferation fades with senescence of mortal lines and is perpetuated in immortal rat hepatoma Fao cell line. In vitro. Cell Dev Biol 1998; 34:163-169.
14. Wolfrom C, Chau NP, Maigné J, Lambert JC, Ducot B, Guerroui S, et al. Evidence for deterministic chaos in aperiodic oscillations of proliferative activity in long-term cultured Fao hepatoma cells. J Cell Sci 2000; 113:1069-1074.
15. Chen Z, Koeneman KS, Corey DR. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 2003; 63:5917-5925.
16. Deschatrette J, Lauga J, Maigné J, Wolfrom C. Telomeres and telomerase activity are regulated as a complex system in cultured hepatoma cells. Complexus 2003; 1:134-141.
17. Deschatrette J, Weiss MC. Characterization of differentiated and dedifferentiated clones of a rat hepatoma. Biochimie 1974; 56:1603-1611.
18. Deschatrette J, Moore EE, Dubois M, Cassio D, Weiss MC. Dedifferentiated variants of a rat hepatoma: reversion analysis. Cell 1980; 19:1043-1051.
19. Maigné J, Ng K, Meunier-Rotival M, Poupon MF, Deschatrette J. Correlation between reversion of a dedifferentiated rat hepatoma line and the recovery of tumorigenicity. Cancer Res 1988; 48:3258-3264.
20. Cornelissen G, Halberg F, Stebbings J, Halberg E, Carandente F, Hsi B. Chronobiometry: with pocket calculators and computer systems. La Ricerca Clin Lab 1980; 10:333-385.
21. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, et al. Expression analysis with oligonucleotide microarrays reveals that myc regulates genes involved in growth, cell cycle, signalling, and adhesion. Proc Natl Acad Sci USA 2000; 7:3260-3265.
22. Dang CV. c-myc target genes involved in cell growth, apoptosis and metabolism. Mol Cell Biol 1999; 19:1-11.
23. Mai S, Hanley-Hyde J, Fluri M. c-myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene 1996; 12:277-288.
24. Bedoyan JK, Lejnine S, Makarov VL, Langmore JP. Condensation of rat telomere-specific nucleosomal arrays containing unusually short DNA repeats and histone H1. J Biol Chem 1996; 271:18485-18493.
25. Promisel-Cooper J, Nimmo ER, Allshire RC, Cech TR. Regulation of telomere length and function by a Myb-domain protein in fission yeast. Nature 1997; 385:744-747.
26. Venditi S, Vega-Palas MA, Di Mauro E. Heterochromatin organization of a natural yeast telomere. Recruitment of Sir3p through interaction with Histone H4 N terminus is required for the establishment of repressive structures. J Biol Chem 1999; 4:1928-1933.
27. Moretti P, Shore D. Multiple interactions in Sir protein recruitment by Rap1p at silencers and telomeres in yeast. Mol Cell Biol 2001; 21:8082-8094.
28. Baur JA, Zou Y, Shay JW, Wright WE. Telomere position effect in human cells. Science 2001; 292:2075-2077.
29. Nautiyal S, DeRisi JL, Blackburn EH. The genome-wide expression response to telomerase deletion in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 2002; 99:9316-9321.
30. Asai A, Kiyozuka Y, Yoshida R, Fujii T, Hioki K, Tsubura A. Telomere length, telomerase activity and telomerase RNA expression in human oesophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res 1998; 18(3A): 1465-1472.
31. Kiyozuka Y, Yamamoto D, Yang J, Uemura Y, Senzaki H, Adachi S, et al. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells. Anticancer Res 2000; 20:203-212.
32. Glass L. Synchronization and rhythmic processes in physiology. Nature 2001; 410:277-284.
33. Shinbrot T, Grebogi C, Ott E, Yorke JA. Using small perturbations to control chaos. Nature 1993; 363:411-417.